Clinical Trials Logo

Liver Failure clinical trials

View clinical trials related to Liver Failure.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT03737448 Suspended - Clinical trials for Acute-On-Chronic Liver Failure

TRimetazidine for acUte on Chronic Liver Failure STudy

TRUST
Start date: November 28, 2018
Phase: Phase 1
Study type: Interventional

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.

NCT ID: NCT02650011 Suspended - Clinical trials for Chronic Liver Disease

Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease

Start date: October 2015
Phase:
Study type: Observational

Chronic liver disease including liver cirrhosis is still associated with high mortality, although advancement of medical management and transplantation. Acute-on-chronic liver failure (ACLF) refers to condition of previously stable chronic liver disease with occurrence of an acute insult resulting in rapid deterioration of liver function and subsequent decompensation. This condition is different from liver cirrhosis (chronic hepatic decompensation) in terms of having more chance of recovery with management before acute deterioration, although it shows high short-term mortality. Thus, earlier recognition and intensive management are important for this condition. However, the definition or diagnostic criteria is unclear and the natural course of this condition is not definitely investigated. The aim of this study is to establish the natural course of ACLF in Korean patients.

NCT ID: NCT01148550 Suspended - Clinical trials for End Stage Liver Disease

Longitudinal Study of Mitochondrial Hepatopathies

MITOHEP
Start date: August 18, 2010
Phase:
Study type: Observational

The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype and phenotype, (3) to determine if circulating biomarkers reflect diagnosis and predict liver disease progression and survival with the native liver, (4) to determine the clinical outcome of these disorders following liver transplantation, and (5) to develop a repository of serum, plasma, urine, tissue and DNA specimens that will be used in ancillary studies. To accomplish these aims, the ChiLDREN investigators at clinical sites (currently 15 sites) will prospectively collect defined data and specimens in a uniform fashion at fixed intervals in a relatively large number of subjects. Clinical information and DNA samples to be collected from subjects and their parents will enhance the potential for meaningful research in these disorders. A biobank of subject specimens and DNA samples will be established for use in ancillary studies to be performed in addition to this study.